Abstract
Objective: When cardiac atrioventricular nodal cells are damaged by disease, the implantation of a cardiac pacemaker becomes necessary. Several limitations and problems of artificial pacemakers have emerged during the past decades. In children and newborn babies with arrhythmia, initial size mismatch and their growth can pose a problem. Lead extraction and infections have additional risks. The aim of our study was the development of a biological cardiac pacemaker by in-vivo adenoviral transfection of ventricular cardiomyocytes in a large animal model with the gene encoding for Adenylate-Cyclase type VI (ACVI) in order to increase the intracellular concentration of cAMP and intrinsic rhythmic rate of the transfected cells, enabling ectopic pacing from the injection site.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
